In the past week, NBIX stock has gone up by 5.34%, with a monthly decline of -0.95% and a quarterly plunge of -0.23%. The volatility ratio for the week is 2.69%, and the volatility levels for the last 30 days are 2.78% for Neurocrine Biosciences, Inc.. The simple moving average for the past 20 days is 2.49% for NBIX’s stock, with a 16.21% simple moving average for the past 200 days.
Is It Worth Investing in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Right Now?
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has a price-to-earnings ratio of 57.65x that is above its average ratio. Additionally, the 36-month beta value for NBIX is 0.29. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NBIX is 96.92M and currently, short sellers hold a 2.50% ratio of that float. The average trading volume of NBIX on April 24, 2024 was 863.45K shares.
NBIX) stock’s latest price update
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has experienced a rise in its stock price by 4.81 compared to its previous closing price of 133.66. However, the company has seen a gain of 5.34% in its stock price over the last five trading days. Invezz reported 2024-03-28 that “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Citigroup repeating the rating for NBIX by listing it as a “Neutral.” The predicted price for NBIX in the upcoming period, according to Citigroup is $127 based on the research report published on December 13, 2023 of the previous year 2023.
Deutsche Bank, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $136. The rating they have provided for NBIX stocks is “Buy” according to the report published on December 12th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to NBIX, setting the target price at $140 in the report published on October 24th of the previous year.
NBIX Trading at 2.96% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.58% of loss for the given period.
Volatility was left at 2.78%, however, over the last 30 days, the volatility rate increased by 2.69%, as shares sank -0.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.89% upper at present.
During the last 5 trading sessions, NBIX rose by +5.34%, which changed the moving average for the period of 200-days by +49.00% in comparison to the 20-day moving average, which settled at $136.67. In addition, Neurocrine Biosciences, Inc. saw 6.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from BENEVICH ERIC, who sale 19,818 shares at the price of $133.36 back on Apr 15 ’24. After this action, BENEVICH ERIC now owns 40,778 shares of Neurocrine Biosciences, Inc., valued at $2,643,020 using the latest closing price.
Delaet Ingrid, the Chief Regulatory Officer of Neurocrine Biosciences, Inc., sale 272 shares at $137.30 during a trade that took place back on Apr 01 ’24, which means that Delaet Ingrid is holding 7,507 shares at $37,346 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc. stands at 0.13. The total capital return value is set at 0.1. Equity return is now at value 12.68, with 8.71 for asset returns.
Based on Neurocrine Biosciences, Inc. (NBIX), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at 0.91. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 54.54.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at 0.44. When we switch over and look at the enterprise to sales, we see a ratio of 7.48. The receivables turnover for the company is 4.3for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.45.
Conclusion
In conclusion, Neurocrine Biosciences, Inc. (NBIX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
